Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1571730
PUBLISHER: Grand View Research | PRODUCT CODE: 1571730
Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Artemisinin Combination Therapy Market Growth & Trends:
The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
Artemisinin Combination Therapy Market Report Highlights:
- Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
- North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
- Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
- Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.
Product Code: GVR-2-68038-592-2
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Artemisinin Combination Therapy Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Artemisinin Combination Therapy Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Artemisinin Combination Therapy Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Artemisinin Combination Therapy Market: Type Movement Analysis, 2023 & 2030 (USD Million)
- 4.3. Artemether+Lumefantrine
- 4.3.1. Artemether+Lumefantrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Artesunate+Amodiaquine
- 4.4.1. Artesunate+Amodiaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Dihydroartemisinin+Piperaquine
- 4.5.1. Dihydroartemisinin+Piperaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Artesunate+Mefloquine
- 4.6.1. Artesunate+Mefloquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Artesunate+Sulfadoxine-Pyrimethamine
- 4.7.1. Artesunate+Sulfadoxine-Pyrimethamine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8. Pyronaridine-Artesunate
- 4.8.1. Pyronaridine-Artesunate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9. Other
- 4.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Artemisinin Combination Therapy Market: Regional Estimates & Trend Analysis
- 5.1. Artemisinin Combination Therapy Market Share, By Region, 2023 & 2030 (USD Million)
- 5.2. North America
- 5.2.1. North America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.2. U.S.
- 5.2.2.1. U.S. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.3. Canada
- 5.2.3.1. Canada Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.4. Mexico
- 5.2.4.1. Mexico Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3. Europe
- 5.3.1. Europe Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.2. U.K.
- 5.3.2.1. U.K. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.3. Germany
- 5.3.3.1. Germany Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.4. France
- 5.3.4.1. France Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.5. Spain
- 5.3.5.1. Spain Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.6. Italy
- 5.3.6.1. Italy Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.7. Sweden
- 5.3.7.1. Sweden Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.8. Norway
- 5.3.8.1. Norway Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.9. Denmark
- 5.3.9.1. Denmark Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Asia Pacific
- 5.4.1. Asia Pacific Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.2. China
- 5.4.2.1. China Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Japan
- 5.4.3.1. Japan Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.4. India
- 5.4.4.1. India Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.5. South Korea
- 5.4.5.1. South Korea Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.6. Australia
- 5.4.6.1. Australia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.7. Thailand
- 5.4.7.1. Thailand Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Latin America
- 5.5.1. Latin America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.2. Brazil
- 5.5.2.1. Brazil Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.3. Argentina
- 5.5.3.1. Argentina Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Middle East and Africa
- 5.6.1. Middle East and Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.2. Saudi Arabia
- 5.6.2.1. Saudi Arabia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.3. UAE
- 5.6.3.1. UAE Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.4. South Africa
- 5.6.4.1. South Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.5. Kuwait
- 5.6.5.1. Kuwait Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis by Key Market Participants
- 6.2. Company Categorization
- 6.3. Company Heat Map Analysis
- 6.4. Company Profiles
- 6.4.1. Advanced Micro Devices
- 6.4.1.1. Participant's Overview
- 6.4.1.2. Financial Performance
- 6.4.1.3. Product Benchmarking
- 6.4.1.4. Recent Developments/ Strategic Initiatives
- 6.4.2. Novartis AG
- 6.4.2.1. Participant's Overview
- 6.4.2.2. Financial Performance
- 6.4.2.3. Product Benchmarking
- 6.4.2.4. Recent Developments/ Strategic Initiatives
- 6.4.3. Sanofi S.A.
- 6.4.3.1. Participant's Overview
- 6.4.3.2. Financial Performance
- 6.4.3.3. Product Benchmarking
- 6.4.3.4. Recent Developments/ Strategic Initiatives
- 6.4.4. Cipla Ltd.
- 6.4.4.1. Participant's Overview
- 6.4.4.2. Financial Performance
- 6.4.4.3. Product Benchmarking
- 6.4.4.4. Recent Developments/ Strategic Initiatives
- 6.4.5. KPC Pharmaceuticals
- 6.4.5.1. Participant's Overview
- 6.4.5.2. Financial Performance
- 6.4.5.3. Product Benchmarking
- 6.4.5.4. Recent Developments/ Strategic Initiatives
- 6.4.6. Fosun Pharmaceutical (Guilin Pharmaceutical)
- 6.4.6.1. Participant's Overview
- 6.4.6.2. Financial Performance
- 6.4.6.3. Product Benchmarking
- 6.4.6.4. Recent Developments/ Strategic Initiatives
- 6.4.7. Ajanta Pharma
- 6.4.7.1. Participant's Overview
- 6.4.7.2. Financial Performance
- 6.4.7.3. Product Benchmarking
- 6.4.7.4. Recent Developments/ Strategic Initiatives
- 6.4.8. Ipca Laboratories Ltd.
- 6.4.8.1. Participant's Overview
- 6.4.8.2. Financial Performance
- 6.4.8.3. Product Benchmarking
- 6.4.8.4. Recent Developments/ Strategic Initiatives
- 6.4.9. Desano Inc.
- 6.4.9.1. Participant's Overview
- 6.4.9.2. Financial Performance
- 6.4.9.3. Product Benchmarking
- 6.4.9.4. Recent Developments/ Strategic Initiatives
- 6.4.10. Hovid Berhad
- 6.4.10.1. Participant's Overview
- 6.4.10.2. Financial Performance
- 6.4.10.3. Product Benchmarking
- 6.4.10.4. Recent Developments/ Strategic Initiatives
- 6.4.11. Mylan
- 6.4.11.1. Participant's Overview
- 6.4.11.2. Financial Performance
- 6.4.11.3. Product Benchmarking
- 6.4.11.4. Recent Developments/ Strategic Initiatives
- 6.4.1. Advanced Micro Devices
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.